Zydus Cadila receives final approval from USFDA for Acyclovir Ointment

19 Mar 2019 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Acyclovir Ointment USP (US RLD - Zovirax), 5%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.

Acyclovir is an antiviral drug which stops the growth of certain viruses. This medication is used to treat the first outbreak of genital herpes infection. It is also used to treat non-life threatening herpes infections of the skin and around the mouth (cold sores) in people with a weakened immune system. The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

923.70 3.80 (0.41%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×